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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comgroups, control, TNF-a and pitavastatin group. Cells of TNF-a group were co-incubated
with different concentrations（10mg/L，20mg /L，30mg /L）ofTNF-a for 24h.Cells of
pitavastatin group were ﬁrstly coincubated with 0.01, 0.1, 1mmol/L pitavastatin
respectively for 1h, then coincubated with 30mg/L TNF-a for 24h. VCAM -1 and miR-
126 mRNA were detected by quantitative reverse transcription polymerase chain reac-
tion (RT-PCR) andWestern blotting was used to detect protein expression of VCAM-1.
Results: Both detection methods have showed that TNF-a stimulation signiﬁcantly
induced the mRNA and protein expression of VCAM-1 in HUVECs in a dose-
dependent manner, and miR-126 mRNA expression exhibited a decreasing trend when
cultured with TNF-a. The increase of VCAM-1 mRNA and protein expression
induced by TNF-a was inhibited by pitavastatin in a dose-dependent manner, too.
However, there were no differences of the expression of miR-126 among three groups.
Conclusions: These effects may explain the ability of pitavastatin to reduce the
progression of atherosclerosis and may increase the stability of plaques. The ﬁndings
further suggest that inhibitory effect of pitavastatin on VCAM-1 is not related to miR-
126 but depends on other things.Characteristic
Odds Ratio
(95% CI) p-value
History of Diabetes Mellitus 1.7 (1.3, 2.2) <0.001
History of CHF 1.6 (1.3, 2.1) <0.001
History of prior CABG 0.7 (0.5, 0.9) 0.007
Low BMI < 18 3.3 (1.2, 9.1) 0.024
High BMI > 30 4.3 (1.5, 12.1) 0.006
Pre-PVI Anemia 2 (1.5, 2.5) <0.001
Creatinine Clearance < 30 ml/min 2.5 (1.8, 3.6) <0.001
Critical Limb Ischemia 1.6 (1.2, 2.1) 0.001
Status – Urgent 2.9 (2.2, 3.7) <0.001
Status – Emergent 7.1 (4.4, 11.4) <0.001
Contrast volume (ml) > 3 x Creatinine Clearance (ml/ 1.5 (1.1, 1.9) 0.003Renal Insufﬁciency and Contrast Nephropathy
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Preprocedural Statin Administration Beneﬁt According To Baseline Renal
Function: A MetaLAnalysis Of Randomized Controlled Trials
Daniele Giacoppo1, Davide Capodanno1, Piera Capranzano1, Patrizia Aruta1,
Corrado Tamburino1
1Ferrarotto Hospital, Catania, Italy
Background: Preprocedural statin administration seems to reduce contrast–induced
acute kidney injury (CI–AKI). This beneﬁt, however, might be limited to patients
without advanced chronic kidney disease.
Methods: Randomized controlled trials (RCTs) comparing preprocedural statin
administration before coronary catheterization with standard strategies were searched
in MEDLINE/PubMed, Embase, Scopus, Web of Science, and ScienceDirect data-
bases. Patients were stratiﬁed in two groups according to a glomerular ﬁltration rate
(GFR) < 60 ml/min or  60 ml/min. A DerSimonian-Laird random-effects model was
used. The endpoint, quantiﬁed and reported as pooled risk ratio (RR) with 95%
conﬁdence interval (CI), was the CI–AKI incidence. Heterogeneity was graded using
the I2 statistic.
Results: Eight RCTs were included. A total of 143 patients (8.5%) with baseline
GFR < 60 ml/min and 112 patients (3.6%) with baseline GFR  60 ml/min developed
CI–AKI. In patients with GFR < 60 ml/min (top panel), the pooled RR indicated
a beneﬁt from statin use(RR 0.67, 95% CI 0.45–1.00, p¼0.50). In patients with GFR
 60 ml/min (bottom panel), the pooled RR indicated a highly signiﬁcant greater
beneﬁt (RR 0.40, 95% CI 0.27–0.61, p< 0.0001) from statin use. I2 was modest in the
ﬁrst analysis (27.5%) and absent in the second(0%).B74 JACC Vol 64/11/Suppl B j September 13–17Conclusions: Statins administration before coronary catheterization leads to a sig-
niﬁcant reduction in the pooled RR of CI-AKI in patients with GFR  60 ml/min.
However a reduced but persistent beneﬁt was seen also in patients with GFR < 60 ml/
min. Larger double–blind RCTs are requested to conﬁrm this results.
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Background: We evaluated the prevalence, predictors, and outcomes of patients who
developed contrast induced nephropathy (CIN) after undergoing percutaneous
vascular intervention (PVI). The association between renal function based contrast
dose and CIN was also explored.
Methods: A total of 13,126 PVI patients from 2010 to 2013 were included in the
analysis. Patients on chronic dialysis or those undergoing a PVI and open vascular
surgery procedure in the same setting were excluded. CIN was deﬁned as an increase
in serum creatinine of  0.5 mg/dl above baseline. A CIN risk model was developed
using logistic regression analysis.
Results: CIN occurred in 3% (400 patients) of the cohort and of these 6.5% (26
patients) developed the need for new dialysis. CIN was strongly associated with
adverse outcome including death (OR 40, CI 26-62.1, p < 0.001), myocardial
infarction (MI) (OR 25.8, CI 15.6-42.6, p < 0.001), TIA/stroke (OR 10.3, CI 4.4-24.2,
p < 0.001), vascular access complications (OR 4, CI 2.8-5.7, p < 0.001), and
transfusion (OR 12.6, CI 10.1-15.7, p < 0.001). Hospital stay was longer in patients
who developed CIN vs. those who did not (non-CIN) (median 9 vs. 2 days respec-
tively, p < 0.001, mean 11.6 vs. 3.8 days respectively, p < 0.001). Predictors of CIN
by logistic regression are shown in the table (Area under the ROC Curve (AUC):
0.789).min)Conclusions: CIN is a common complication associated with PVI and strongly
associated with the risk of in-hospital death, MI, stroke, transfusion and increased
hospital length of stay. Clinical predictors of CIN include high and low body weight,
diabetes, heart failure, anemia, baseline renal dysfunction, critical limb ischemia and a
higher acuity of the PVI procedure. Exceeding a contrast dose of greater than three
times the creatinine clearance was strongly associated with CIN, and suggests the need
for minimizing contrast dose in patients undergoing PVI.
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Background: TAVR is a lifesaving procedure for many patients at high risk for
surgical aortic valve replacement. The prevalence of CKD and risk for contrast-
induced nephropathy in this population is high. A very low contrast dose CTA pro-
tocol enabling comprehensive cardiac and vascular imaging would be valuable in this
fragile patient population., 2014 j TCT Abstracts/Renal Insufﬁciency and Contrast Nephropathy
